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Background: Blood biomarkers are valuable tools for elucidating complex cellular and
molecular mechanisms underlying traumatic brain injury (TBI). Profiling distinct classes
of biomarkers could aid in the identification and characterization of initial injury and
secondary pathological processes. This study characterized the prognostic perfor-
mance of a recently developed multi-marker panel of circulating biomarkers that reflect
specific pathogenic mechanisms including neuroinflammation, oxidative damage, and
neuroregeneration, in moderate-to-severe TBI patients.
Materials and methods: Peripheral blood was drawn from 85 isolated TBI patients
(n=60 severe, n=25moderate) at hospital admission, 6-, 12-, and 24-h post-injury. Mor-
tality and neurological outcome were assessed using the extended Glasgow Outcome
Scale. A multiplex platform was designed on MULTI-SPOT® plates to simultaneously
analyze human plasma levels of s100 calcium binding protein beta (s100B), glial fibrillary
acidic protein (GFAP), neuron specific enolase (NSE), brain-derived neurotrophic factor
(BDNF), monocyte chemoattractant protein (MCP)-1, intercellular adhesion molecule
(ICAM)-5, and peroxiredoxin (PRDX)-6. Multivariable logistic regression and area under
the receiver-operating characteristic curve (AUC) were used to evaluate both individual
and combined predictive abilities of these markers for 6-month neurological outcome
and mortality after TBI.
Results: Unfavorable neurological outcome was associated with elevations in s100B,
GFAP, and MCP-1. Mortality was related to differences in six of the seven markers
analyzed. Combined admission concentrations of s100B, GFAP, and MCP-1 were able
to discriminate favorable versus unfavorable outcome (AUC=0.83), and survival versus
Frontiers in Neurology | www.frontiersin.org May 2015 | Volume 6 | Article 1101
Di Battista et al. Neuroinjury biomarkers in moderate-to-severe TBI
death (AUC=0.87), although not significantly better than s100B alone (AUC=0.82 and
0.86, respectively).
Conclusion: The multi-marker panel of TBI-related biomarkers performed well in
discriminating unfavorable and favorable outcomes in the acute period after moderate-
to-severe TBI. However, the combination of these biomarkers did not outperform s100B
alone.
Keywords: s100B, GFAP, NSE, BDNF, MCP-1, ICAM-5, PRDX-6
Introduction
The multifactorial nature of secondary injury after traumatic
brain injury (TBI), especially the complex networks of molecular
pathways mediating cellular damage in different brain regions,
has confounded attempts to elucidate the pathology underlying
injury progression (1). In addition, the extracranial effects of
trauma must be considered as these are often critical factors in
the death of TBI patients (2). In recent years, the application
of brain-specific markers of neuronal, glial, and axonal damage,
identified in the peripheral blood, has shown potential clinical
utility in neurointensive care as diagnostic, prognostic, and mon-
itoring adjuncts (3). Identifying sensitive and reliable biomarkers
associated with patient outcome may improve our understanding
of structural brain damage or underlying cellular pathogenesis and
regenerativemechanisms after brain trauma (4). This information
can be used to guide future basic and clinical research, with the
aim of improving patient care and outcomes (5).
The peripheral blood can be used as a source of biomarkers
indicative of neuropathology across the spectrumofmild to severe
brain injury (6). It has been proposed that damage to brain tis-
sue after a TBI may initiate local metabolic and inflammatory
processes, resulting in the release of a number of inflammatory
mediators and damage-associated molecular pattern (DAMP)
molecules (7, 8). Thesemolecules then cross a dysfunctional blood
brain barrier (BBB) and enter the circulation to recruit peripheral
immune cells to the brain, initiating bidirectional communication
between the CNS and the systemic immune system (8–10). Thus,
peripheral blood samplesmay containmolecules derived from the
CNS and/or the periphery as a secondary response to injury.
Several blood-borne biomarker candidates have been investi-
gated either individually or collectively across the spectrumof TBI
severity. In particular, s100 calcium binding protein beta (s100B)
and neuron specific enolase (NSE) have been widely studied,
and elevated circulating concentrations of these markers may
be associated with secondary injury progression (11) and poor
prognosis (12, 13). Additionally, inflammatory cytokines, such
as Interleukin (IL)-1β, -6, -8, and -10, are associated with poor
outcome following severe TBI (14, 15). However, examination of
single DAMP molecules, such as s100B, may lack specificity due
to extracranial sources (16, 17). Furthermore, systemic inflamma-
tory markers are often pleiotropic in nature and thus difficult to
individually link to TBI.
Thus, a multi-marker approach to characterizing TBI out-
come has been advocated, since the simultaneous estimation
of multiple markers to establish a “biological signature” may
provemore effective in encompassing themultisystemic character
of secondary injury pathology, and may increase diagnostic
and prognostic accuracy (18). For example, Gradisek et al. (19)
demonstrated that admission blood levels of s100B and glial fibril-
lary acidic protein (GFAP) together accurately discerned survivors
from non-survivors 1 year following TBI, and Diaz-Arrastia et al.
(20) found the combination of ubiquitin C-terminal hydrolase-1
(UCH-L1) andGFAP out performed eithermarker individually in
discriminating TBI patients fromhealthy controls. However, these
studies did not include markers reflecting additional secondary
injury processes such as inflammation and oxidative damage. In
view of this, Buonora et al. (21) recently employed a multivari-
ate approach to TBI diagnosis by simultaneously assessing seven
blood biomarkers, each associated with a specific TBI-related
injury process: NSE relating to neuronal injury; brain-derived
neurotrophic factor (BDNF) for neuronal repair; peroxiredoxin
(PRDX)-6 for oxidative damage; GFAP and s100B for glial dam-
age; monocyte chemoattractant protein (MCP)-1 for immune
activation; intercellular adhesion molecule (ICAM)-5 for disrup-
tion of intercellular adhesion processes. The authors reported
that a novel multi-marker panel, detectable in peripheral blood,
demonstrated diagnostic utility specifically for mTBI and poten-
tially for the full spectrum of brain injury (21). However, while
this multi-marker panel shows promise in acute TBI diagnosis,
the prognostic utility of these markers for longer-term outcome
in more severely injured patients has not been assessed.
Hence, the purpose of this study was to further examine a
recently developed panel of 7 biomarkers in a cohort of moderate-
to-severe TBI patients. The two specific aims were (1) to charac-
terize the temporal profile of plasma s100B, GFAP, NSE, BDNF,
MCP-1, ICAM-5, and PRDX-6 concentrations at four time-points
within the first 24 h of hospital admission, stratified according to
patient outcomes, (2) to compare the individual and collective
utility of these markers in discriminating between favorable and
unfavorable patient outcomes.
Materials and Methods
Study Population and Enrollment
Potential study participants were admitted to Sunnybrook Health
Sciences Centre and St. Michael’s Hospital (Toronto, ON,
Canada). Upon admission, the trauma team/emergency room
personnel enrolled patients who met the initial criteria of sustain-
ing an isolated TBI, defined by a Glasgow Coma Score of <13
and a non-head abbreviated injury score (AIS) 2; TBI patients
were further dichotomized into moderate (GCS 9–12) and severe
(GCS 3–8) injury. Consent for enrollment was obtained from a
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substitute decision maker. If this was not possible, consent was
delayed in accordance with the Tri-Council Policy Agreement
for Research in Emergency Health Situations (Article 2.8), and
obtained from next-of-kin. If the patient recovered sufficiently to
provide consent, their consent was also obtained. Patients were
excluded in the following cases: an elapsed time between trauma
and hospital admission in excess of 3 h,<16 years of age, pregnant,
lacking vital signs prior to admission, or clinically brain dead
on admission. The study protocol was approved by the Research
Ethics Boards at Sunnybrook Health Sciences Centre and St.
Michaels Hospital. Blood samples were drawn from healthy vol-
unteers after obtaining written informed consent in accordance
with the principles of the Declaration of Helsinki.
Study Design and Procedures
At hospital admission, demographic data were obtained from
study patients alongwith a number of clinical indices. This process
has been described in detail previously (21). Briefly, mechanism
of injury, elapsed time from trauma to the emergency room,
and neurological status were recorded. Past medical history was
obtained along with routine laboratory exams, including a com-
puterized tomography (CT) scan. All significant events up to
hospital discharge, death or 28 days were recorded. In the instance
of patient death, cause of death was recorded as TBI or non-TBI
related. The extended Glasgow Outcome Scale (GOSE) was used
to assess patient outcome at hospital discharge, at 28 days, and at
6-month post-injury.
Blood Sample Collection and Analysis
Venous blood samples were collected at hospital admission, and
then again at 6-, 12-, and 24-h post-injury. Samples were drawn
into 10-mlK2EDTA (with 4mMsodiummetabisulfite [Na2S2O5])
or 10-ml sodium heparin vacutainers (Vacutainer, Becton Dick-
inson, Rutherford, NJ, USA). The samples were immediately cen-
trifuged at 1600 g for 15min at 4°C, and the plasma supernatant
was aliquoted into six (1–2ml) aliquots and frozen at 70°C until
subsequent analysis. Analysis of BDNF, GFAP, MCP-1, ICAM-
5, NSE, and s100B plasma concentrations was performed using
a multiplex immunoassay system, while plasma PRDX-6 was
assessed using a single-plex immunoassay system. All assays were
performed on the meso scale discovery (MSD) SECTOR® Imager
6000 (MSD, Gainsburg, MD, USA), as previously described (21).
The lower limit of detection (LLOD) and lower limit of quan-
titation (LLOQ) were defined as 3 and 10 times the SD of the
averaged 0 for each assay, respectively. All samples were run in
triplicate-<3 and<10% intra- and inter-assay variability, respec-
tively, was observed for all multiplex samples, while all single-plex
samples displayed<4 and<13% intra- and inter-assay variability,
respectively.
Statistical Analysis
Clinical and demographic data are represented as the mean SD
unless otherwise noted. The normality of each variable was
assessed before the appropriate statistical test was applied.
To examine 6-month neurological outcome, patients were
dichotomized into favorable (GOSE 5–8) and unfavorable (GOSE
1–4) outcome groups. Similarly, patients were also stratified into
two groups, “Lived” and “Died” to assess mortality. Group clas-
sifications for both neurological outcome and mortality were
analyzed at each time-point using either a Student’s t-test or
Mann–Whitney U, where appropriate. To investigate the prog-
nostic utility of peripheral blood markers, admission levels of
each marker were used to discriminate between favorable ver-
sus unfavorable 6-month neurological outcome, and lived versus
died using single ormulti-marker receiver–operator characteristic
(ROC) curves. Multiple-marker ROC curves were compared to
single-marker curves using binary logistic regression analysis fol-
lowed by the chi-squared statistic. Statistical significance was set at
(p 0.05) for all analyses. All data were analyzed using GraphPad
Prism Version 6.0d (GraphPad Inc., CA, USA) and Stata Version
13.1 (StataCorp, TX, USA).
Results
Demographic and Clinical Characteristics
Clinical and demographic data for all TBI patients are described in
Table 1. Of the 85 TBI patients, 25 were moderate, and 60 severe.
The average age of the patients was 45.8 21.9 years. Twenty
patients (23.5%) developed sepsis, and 50 patients (58.8%) had
an unfavorable neurological outcome as described by a 6-month
GOSE score of 1–4. The mortality rate was 28.2%, and half of all
deaths resulted from organ failure.
Plasma Concentrations of Neuroinjury Markers
Stratified by Clinical Indices
6-Month Neurological Outcome
Significant differences in three of the seven markers were iden-
tified in patients with unfavorable versus favorable 6-month
TABLE 1 | Demographic, clinical, and outcome data of brain-injured
patients.
Characteristics All patients
(n= 85)
Moderate TBI
(n= 25)
Severe TBI
(n= 60)
Demographics
Age (years) 45.821.9 47.921.7 44.922.2
Male gender – n (%) 66 (77.6) 19 (76.0) 47 (78.3)
Clinical characteristics
Trauma type – n (%)
Blunt 83 (97.6) 24 (96.0) 59 (98.3)
Penetrating 2 (2.3) 1 (4.0) 1 (1.7)
Time to ED (min) 79.656.4 72.352.0 82.758.2
ISS score 23.611.0 19.112.5 25.49.8
AIS head 4.21.1 3.61.2 4.41.0
GCS 6.53.3 10.81.2 4.632.0
Positive CT – n (%) 70 (82.3) 18 (72.0) 52 (86.7)
Positive serum ethanol – n (%) 27 (31.8) 10 (40.0) 17 (31.7)
Pre-injury comorbidities – n (%) 27 (31.8) 11 (44.0) 16 (26.7)
Pre-injury beta-blocker use – n (%) 4 (4.7) 1 (4.0) 3 (5.0)
Neurosurgical intervention – n (%) 25 (29.4) 3 (12.0) 22 (36.7)
Outcomes
Mortality – n (%) 24 (28.2) – 24 (40.0)
Unfavorable outcome – n (%) 50 (58.8) 8 (32.0) 42 (70.0)
Sepsis infection – n (%) 20 (23.5) 6 (24.0) 14 (23.3)
Organ failure – n (%) 12 (14.1) – 12 (20.0)
TBI, traumatic brain injury; ED, emergency department; ISS, injury severity score; AIS,
abbreviated injury scale; GCS, Glasgow coma scale; GOSE, Glasgow outcome scale
extended.
Moderate TBI=GCS 9–12; Severe TBI=GCS 3–8.
Unless otherwise stated, results are expressed as meanSD.
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neurological outcome (Figures 1A–G). The largest difference was
observed in GFAP, which displayed a nearly seven-fold eleva-
tion in patients with unfavorable outcome at hospital admission
versus those with a favorable outcome (5.05 versus 0.74 ng/ml),
and remained significantly elevated at each sampled time-point
within the first 24 h (Figure 1B). Admission plasma s100B levels
displayed a near four-fold increase in those with unfavorable
outcome (Figure 1A). Similar to GFAP, s100B remained signifi-
cantly elevated throughout the first 24 h (Figure 1A). Admission
and 12 h plasma concentrations of MCP-1 were also significantly
elevated in patients with an unfavorable outcome (Figure 1E).
Mortality
Six of the seven neuroinjury markers were significantly different
between survivors and non-survivors (Figures 2A–G). Similar to
6-month neurological outcome, GFAP levels at hospital admis-
sion were significantly elevated among patients who died com-
pared with those who lived (eleven-fold increase, 9.612 versus
0.86 ng/ml) (Figure 2B). GFAP levels remained significantly ele-
vated in patients who died at all sampled time-points (Figure 2B).
Admission levels of s100B were nearly five-fold higher in patients
who died as compared to those who lived, and remained elevated
at all time-points (Figure 2A). At 6 h, both NSE and MCP-1
levels were significantly higher in non-survivors versus survivors
(Figures 2C,E, respectively). At 24 h, BDNF and ICAM-5 lev-
els were significantly decreased and increased, respectively, in
patients who died (Figures 2D,F, respectively).
ROC Curve Analysis
See Table 2 for individual marker AUC values – each marker was
evaluated for their ability to discriminate favorable versus unfa-
vorable 6-month neurological outcome, and survival versus death.
Admission plasma concentrations of s100B, GFAP, and MCP-
1 were significantly associated with both unfavorable outcome
and mortality (Table 2). s100B displayed the strongest relation-
ship to adverse 6-month neurological outcome (AUC= 82.5) and
mortality (AUC= 86.5) (Table 2).
Multivariate models were created using the significant indi-
vidual predictors of unfavorable 6-month neurological outcome
and mortality to create multi-marker ROC curves. This model,
which consisted of s100B, GFAP, andMCP-1, did not significantly
differ from s100B alone in discriminating favorable from unfa-
vorable outcome (AUC= 0.83 versus AUC= 0.82) (Figure 3).
Similarly, multivariate model discrimination of mortality from
survival (AUC= 0.87) was not significantly different than that of
s100B alone (AUC= 0.86) (Figure 4).
Discussion
This study characterized peripheral blood s100B, GFAP, NSE,
BDNF, MCP-1, ICAM-5, and PRDX-6 levels over the first 24 h
post-hospital admission in 85 moderate-to-severe TBI patients.
We identified significantly elevated concentrations of s100B and
GFAP at all sample time points (admission, 6-, 12-, 24-h) in
patients with unfavorable neurological outcome at 6months and
in those who died. This is in agreement with previous studies that
found high levels of s100B and GFAP were associated with poor
outcome at 1–6months post-TBI.While we found no relationship
between NSE and 6-month neurological outcome, mortality was
associated with elevations of NSE at 6 h after hospital admission.
Our results are in accord with prior findings that identified a
relationship between blood NSE levels early after injury, andmor-
tality (19). Furthermore, our results are also consistent with others
who found elevated NSE levels beyond the first 24 h after hospital
admission in association with patient death (22, 23). However,
previous studies have also reported a correlation betweenNSE and
unfavorable neurological outcome (22–26). The reasons for these
discordant findings are unclear, but may relate to methodological
differences involving sample times (22), heterogeneous patient
populations (23), and varied outcome stratificationmeasures (24).
Both CNS and systemic inflammation are critical components
to secondary injury after TBI (9, 27, 28). While the role of innate
immunity after TBI is poorly understood, it has been theorized
that local inflammation, in response to the initial trauma initi-
ates a cascade of events that include the recruitment of periph-
eral leukocytes to the brain, potentially exacerbating brain tissue
injury (29, 30). In view of this, ICAM-5 andMCP-1 are inflamma-
tory molecules potentially involved in aiding peripheral leukocyte
mobilization. ICAM-5 is found primarily in telencephalic neurons
(31), and is involved in the activation and migration of leukocytes
across the endothelium (32). MCP-1 is a chemoattractant protein
secreted from both mononuclear and neuronal cells that facili-
tates monocyte and macrophage mobilization (29, 33, 34). In the
present study, ICAM-5 levels were significantly elevated at 24 h
after hospital admission in non-survivors compared to survivors.
Our previous work characterized peripheral blood ICAM-5 con-
centrations after TBI, and identified decreased levels in moderate
and severe TBI patients acutely after hospital admission (21). To
our knowledge, no studies have examined the association between
plasma ICAM-5 levels and patient outcome in the acute period
after TBI. It is possible that our previously reported decrease of
ICAM-5 acutely after moderate and severe TBI may have masked
elevations observed in a subset of non-survivors. Additionally,
we found MCP-1 was significantly increased at admission and
12 h in those with unfavorable neurological outcome, as well
as at admission and 6 h in those who died. These findings are
aligned with previous work by Rhodes et al. (35), who identified
elevated MCP-1 levels in the blood of severe TBI patients who
died compared with survivors. Furthermore, in a rodent model
of TBI, Semple et al. (29) identified a role for MCP-1 in delaying
functional recovery after closed head injury. In the present study,
our findings in both ICAM-5 and MCP-1 are consistent with
immunopathological communication between the CNS and the
periphery.
Secondary injury after TBI not only encompasses damage-
related processes that worsen brain injury, but also an altered state
of tissue regeneration and repair (36). In view of this, BDNF has
been proposed as a potential biomarker reflecting the neuroregen-
erative response to TBI (37). BDNF is the most abundant brain
neurotrophin, involved in promoting neuron survival, differen-
tiation, and outgrowth (38, 39). In the present study, we found
significantly decreased plasma levels of BDNF at 24 h after hospi-
tal admission in non-survivors versus survivors. In our previous
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FIGURE 1 | Plasma concentrations of neuroinjury biomarkers in
combined moderate-to-severe TBI patients within the first 24 h of
hospital admission, stratified according to 6-month neurological
outcome using the extended Glasgow outcome scale (GOSE) score.
Favorable outcome=GOSE 5–8, n=35; Unfavorable outcome=GOSE 1–4,
n= 50. s100 calcium binding protein (A), glial fibrillary acidic protein (B), neuron
specific enolase (C), brain-derived neurotrophic factor (D), monocyte
chemoattractant protein-1 (E), intercellular adhesion molecule-5 (F),
peroxiredoxin-6 (G). Sample sizes may vary. *p0.05 by Student’s t-test or
Mann–Whitney U, where appropriate, versus patients with a favorable outcome.
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FIGURE 2 | Plasma concentrations of neuroinjury biomarkers in
combined moderate-to-severe TBI patients within the first 24 h of
hospital admission, stratified by patients who lived versus died. Lived,
n= 61; Died, n= 24. s100 calcium binding protein (A), glial fibrillary acidic
protein (B), neuron specific enolase (C), brain-derived neurotrophic factor (D),
monocyte chemoattractant protein-1 (E), intercellular adhesion molecule-5 (F),
peroxiredoxin-6 (G). Sample sizes may vary. *p0.05 by Student’s t-test or
Mann–Whitney U, where appropriate, versus patients who survived.
work,we identified elevated levels of circulatingBDNFwithin 24 h
of hospital admission in moderate and severe TBI patients (21).
This suggests that BDNF may be upregulated after injury in
response to neuronal damage, although an inadequate BDNF
response may negatively impact patient outcome. In view of
this, animal model research has identified associations between
increased hippocampal BDNF levels and functional recovery after
TBI (40), and the Val66Met polymorphism of the BDNF gene,
which interferes with BDNF secretion, has been associated with
poor outcome in human subarachnoid hemorrhage survivors
(41). However, this polymorphism has also been associated with
improved functional recovery of executive functioning after TBI
(42). It is important to note that these studies evaluated BDNF
gene alleles in association with patient recovery from months
to years after injury, while we assessed plasma BDNF protein
concentrations in the acute period after TBI. Differences in both
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TABLE 2 | Single-marker AUC values for clinical indices.
Marker Unfavorable outcome Mortality
s100B 82.50.05* 86.50.04*
GFAP 71.50.06* 79.50.06*
NSE 59.50.06 61.30.07
BDNF 48.50.07 47.80.08
MCP-1 65.30.06* 70.20.06*
ICAM-5 46.40.07 62.40.07*
PRDX-6 48.60.07 56.10.07
Data represented as AUCSE.
*p<0.05 by logistic regression analysis.
FIGURE 3 | ROC curves of neuroinjury biomarkers used to
discriminate unfavorable versus favorable 6-month neurological
outcome in TBI patients. A combined AUC consisting of s100B, GFAP, and
MCP-1 was not statistically better than s100B alone in discriminating
unfavorable from favorable outcome by chi-squared.
FIGURE 4 | ROC curves of neuroinjury markers used to discriminate
death from survival in TBI patients. A combined AUC consisting of s100B,
GFAP, and MCP-1 was not statistically better than s100B alone in
discriminating death from survival by chi-squared.
study design and experimental approach may account for the het-
erogeneity in findings. We also characterized PRDX-6, an antiox-
idant enzyme found primarily in astrocytes (43). PRDX-6 has a
purported role in protecting brain tissue fromneurodegeneration,
specifically preventing neuronal damage via lipid peroxidation
and cell death signaling related to hypoxia (43, 44). However, the
role of PRDX-6 in TBI is unclear. Manevich et al. (43) found
elevated levels of the oxidated (inactive) form of PRDX-6 in the
CSF of severe TBI patients, and we previously found elevated
plasma levels of PRDX-6 in TBI patients (21). However, in the
present study, we did not find any association between plasma lev-
els of PRDX-6 and unfavorable neurological outcome ormortality.
It is possible that PRDX-6 has utility as a diagnosticmarker in TBI,
while its prognostic capabilities may be limited.
In the current study, a multiple-marker model consisting of
s100B, GFAP, and MCP-1 did not yield significantly higher AUC
values for discriminating unfavorable from favorable outcomes
after TBI compared to s100B alone. Previous TBI studies that
have characterized biomarkers in relation to patient outcomes
have often evaluated markers individually (14, 24), or used a
combined-approach consisting of a single marker with other clin-
ical indices (e.g., CT scan results) (3, 22). However, the purpose
of our study was to evaluate single versus multiple biomarkers
alone, absent clinical indices, and few studies have done this to
date. In agreement with our findings, DeFazio et al. (45) found
that admission levels of plasma s100B were associated with poor
status in severe TBI patients at 72 h, and that this relationship
was not improved upon by a multivariate model including D-
dimer and s100B at 24 h. Conversely, Berger et al. (46) found
the combination of s100B, NSE, and myelin basic protein (MBP)
improved outcome prediction in pediatric TBI. Although we
did not find a significant difference in outcome discrimination
between multiple and individual markers, we did not assess MBP,
and only evaluated adult TBI patients. In addition, Gradisek et al.
(19) found s100B together with GFAP improved 1-year mortality
prediction. However, thesemarkers were used to predictmortality
in patients who succumbed to brain-related deaths. In the same
study, there was no association between these biomarkers and
non-brain-related deaths such as multiple organ failure (19). In
view of this, we included all causes of mortality in our non-
survivor group. It is likely that following a TBI, brain-related
death and subsequent organ failure reflect different pathological
mechanisms, and may require specific biological signatures for
their detection. Furthermore, our finding of s100B alone to be
associated with global outcome and mortality following TBI may
reflect its role as an inflammatory mediator in the peripheral
blood. Beyond its role as a possible marker of brain tissue damage,
s100B also acts as a ligand on numerous cell types, including
peripheral leukocytes, which express the receptor for advanced
glycation end-products (RAGE) (47, 48). This signaling cascade
propagates an inflammatory response (47) and thus may play a
role in post-TBI complications such as multiple organ failure,
which is known to have an inflammatory pathology (49).
Despite having a robust sample size to characterize TBI, a
larger patient cohort would have been required for further sub-
stratifications, particularly to dichotomize moderate and severe
patients; we were unable to assess outcome and mortality in
isolated severe and moderate injures due to a lack of moder-
ately injured patients with unfavorable outcomes. Future studies
should also consider incorporating multiple-marker panels relat-
ing biological molecules to brain-specific clinical indices such as
intracranial pressure and specific CT scan classifications, as well as
associated systemic outcomes of TBI including sepsis andmultiple
organ failure.
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Conclusion
Traumatic brain injury elicits the release of a number of
neuroinjury molecules that are easily assessed in the periph-
eral blood and hold promise in the clinical management of
patients. In the present study, elevated levels of s100B, GFAP,
and MCP-1 in the peripheral blood of TBI patients within
24 h of hospital admission were associated with both unfavor-
able 6-month neurological outcome and death. Despite promis-
ing evidence of multi-marker algorithms displaying enhanced
utility to discriminate between healthy individuals and TBI
patients, under the current approach, the combination of
each individual marker did not yield greater integrated dis-
crimination beyond the single-marker s100B in moderate-to-
severe TBI.
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